NEWS - Dec 7, 2020 Relmada Therapeutics Announces Initiation of Phase 3 Program for REL-1017 as Adjunctive Treatment for Patients with Major Depressive Disorder Read more
NEWS - Oct 27, 2020 Relmada Therapeutics Expands R&D Team, Appoints Paolo Manfredi, M.D., as Acting Chief Scientific Officer, Marco Pappagallo, M.D., as Acting Chief Medical Officer and Updates R&D Milestones Read more
NEWS - Jul 13, 2020 Relmada Therapeutics Announces Uplisting to the Nasdaq Global Select Market® Read more
NEWS - Jun 23, 2020 Relmada Therapeutics Announces Notice of Allowance for Patent in Canada Covering REL-1017 for Treatment of Psychiatric Symptoms Read more
NEWS - Jun 9, 2020 Relmada Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference Read more
NEWS - May 29, 2020 Relmada Therapeutics to Present at the Jefferies 2020 Virtual Healthcare Conference Read more
NEWS - May 27, 2020 Relmada Therapeutics Announces Outcome of End-of-Phase 2 Meeting with FDA for REL-1017 for Adjunctive Treatment of Patients with Major Depressive Disorder Read more
NEWS - May 26, 2020 Relmada Therapeutics Appoints Molly Harper as Executive Vice President of Operations Read more
NEWS - Apr 28, 2020 Relmada Therapeutics Enhances Senior Leadership Team with Appointment of Brian A. Walter, Ph.D., as Vice President of Regulatory Affairs Read more
